Novartis ends ALS program after phase 2 flop, adding to R&D woes
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Novartis ends ALS program after phase 2 flop, adding to R&D woes" is generating significant coverage in the Business category, with 1 articles from 1 distinct sources tracked by PULSE so far.
Outlets currently covering the story include BioSpace. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 58d ago.
Quick answers
Why is "Novartis ends ALS program after phase 2 flop, adding to R&D woes" trending?
Because 1 independent news sources published 1 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (1)
- Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month BioSpace · 58d ago
Topics
Related trends
Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors
Medical experts are stunned after the promising cholesterol drug pelacarsen unexpectedly fails a key study, leading to its abandonment.
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
Rebecca Gayheart details Eric Dane’s final week of life: ‘Had no idea that was it’
Rebecca Gayheart details Eric Dane's final week and brutal ALS decline in her first broadcast appearance following his death.
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.
Eric Dane Daughter Saved Him from Drowning During ALS Battle, Revealed in Posthumous Book
Eric Dane’s posthumous memoir reveals his daughter rescued him from drowning amid his ALS battle, sparking a wave of tributes.
New Orleans Saints legend Steve Gleason reflects on his 15-year ALS fight
New Orleans Saints legend Steve Gleason is honored during the twentieth anniversary of the Superdome reopening.